Radiotherapy of Advanced Carcinoma of the Oropharyngeal Region Under Hyperbaric Oxygenation

Chang, Chu H.; Conley, John; Herbert, Charles

doi:10.2214/ajr.117.3.509

Cited by 34 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Teguh et al found that Patients, who receive HBOT after tumor radiotherapy in mouth and fossa, have better QOL scores (13). CHU H et al concluded that HBOT is a good adjuvant in radiotherapy for advanced oropharyngeal cancer (38). These results are relevant to our systematic review.…”

Section: Tonsillar Fossa Tumor Radiotherapymentioning

confidence: 59%

Hyperbaric Oxygen Therapy and Quality of Life: A Systematic Review

Nourmohammadi

Doaee

Fazel

et al. 2017

Ann Mil Health Sci Res

View full text Add to dashboard Cite

Objective: Hyperbaric oxygen therapy (HBOT) involves breathing pure oxygen in a high-pressure chamber. HBOT is a wellestablished treatment for several diseases, such as serious infections, chronic diabetic foot ulcer, radiation injury, and hidradenitis suppurativa. There are various troublesome diseases that decrease pleasure in life in patients. HBOT has excellent effects in improving QOL in patients with acute and chronic diseases. The present study aimed at assessing the researches that focus on improving the QOL after HBO treatments. Methods:A systematic quest was conducted to evaluate English papers (clinical trials) that were published before April 2017. We searched PubMed, institute of scientific information (ISI), SCOPUS, Web of Science, Ovid, Science direct, ProQuest, Wiley, Cochran, Ebsco host, and Google Scholar. The reference lists of all the articles and electronic journals were searched for further studies. The JAMA users guide evaluation scales for RCTs was used to assess quality of the researched articles. Inclusion and exclusion criteria were extracted according to the scientific criteria. Sample size was 806 patients.Results: Finally, 15 published articles were extracted. Most researches were done in UK (26.7%), Israel (20%), and Sweden (20%). The mean age in HBOT group was 41.88, with a male to female ratio of 1.52. The mean age in the control group was 38.29, with a male to female ratio of 2.14. The most frequent clinical trials were those on the treatment of diabetic foot ulcer (20%), post-concussion syndrome (13.3%), pelvic radiotherapy (13.3%), and chronic arm lymphedema after radiotherapy (13.3%). The most QOL questionnaires used were SF-36 (21.4%), EORTC (European organization for research and treatment of cancer) QLQ-C30, head and neck cancer module (H&N35), and performance status scale (PSS).Conclusions: A significant effect of HBOT on improving QOL in patients' outcomes and symptoms was found compared with the control group. We found improved QOL in patients with diabetic foot ulcer, post-concussion syndrome, pelvic radiotherapy, post stroke, hidradenitis suppurativa, tonsillar fossa tumor radiotherapy, jaw osteonecrosis, and fibromyalgia syndrome. We suggest that HBOT be added to conventional treatment of these patients as an adjuvant.

show abstract

Section: Tonsillar Fossa Tumor Radiotherapymentioning

confidence: 59%

Hyperbaric Oxygen Therapy and Quality of Life: A Systematic Review

Nourmohammadi

Doaee

Fazel

et al. 2017

Ann Mil Health Sci Res

View full text Add to dashboard Cite

show abstract

“…The included trials were published between 1967 and 1999, and the review authors are unaware of any ongoing RCTs in the area. The trials report data concerning the treatment of malignant tumours from several di erent sites: head and neck (Berry 1979;Chang 1973;Ha y 1999;Henk 1977a;Henk 1986;Sause 1979;Sealy 1986;Shigematsu 1973;Tobin 1971;Van Den Brenk 1968); uterine cervix (Brady 1981;Dische 1999;Fletcher 1977;Glassburn 1974;Tobin 1971;Ward 1979;Watson 1978); urinary bladder (Cade 1967;Cade 1978;Plenk 1972;Tobin 1971;Van Den Brenk 1968); bronchus (Cade 1967); rectum (Tobin 1971); brain (Tobin 1971); and oesophagus (Tobin 1971). The included trials enrolled a total of 2286 participants, of which 1103 were allocated to receive HBO and 1153 to control (no allocation information was available for 30 participants).…”

Section: Included Studiesmentioning

confidence: 99%

“…Although not stated in the report, it is likely this was also true of Henk 1977a, as this trial was undertaken under the auspices of the same group (British Medical Council). Three trials also employed a sealed-envelope system (Chang 1973;Ha y 1999;Sealy 1986), while Plenk 1972 used a random number table, and Tobin 1971 a card drawn by a disinterested person. The method of randomisation was not stated in four studies (Brady 1981;Fletcher 1977;Glassburn 1974;Sause 1979), and was quasi-random in two studies: Shigematsu 1973 employed a method based on the registration number, while Van Den Brenk 1968 used birth date.…”

Section: Randomisationmentioning

confidence: 99%

“…Nine studies reported no losses to follow-up (Berry 1979;Cade 1967;Chang 1973;Fletcher 1977;Glassburn 1974;Ha y 1999;Shigematsu 1973;Van Den Brenk 1968;Watson 1978). Two studies reported analysing participants randomised to receive HBO in the control group (Berry 1979;Ward 1979), while 10 studies reported losses to follow-up, none of which appeared in the analysis in those reports.…”

Section: Intention-to-treat Analysismentioning

confidence: 99%

“…Nine trials reported this outcome (Berry 1979;Chang 1973;Ha y 1999;Henk 1977a;Henk 1986;Sealy 1986;Shigematsu 1973;Tobin 1971;Van Den Brenk 1968), for 710 participants a er exclusion of withdrawals (31% of the total participants in this review), with 339 (48%) allocated to HBOT and 371 (52%) to control. Over all fractionation schemes, there was a reduction in the proportion of participants dying within one year a er receiving radiation therapy with HBOT (risk ratio (RR) of death with HBOT was 0.83, 95% confidence interval (CI) 0.70 to 0.98 (Analysis 1.1).…”

Section: Mortality At One Year With Head and Neck Cancermentioning

confidence: 99%

See 2 more Smart Citations

Hyperbaric oxygenation for tumour sensitisation to radiotherapy

Bennett

Feldmeier

Smee

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Hyperbaric oxygen in radiation therapy

Glassburn¹,

Brady²,

Plenk³

1977

Cancer

View full text Add to dashboard Cite

The importance of oxygen with low LET radiations has been established beyond any doubt in many different systems, both plant and animal. While some studies, especially head and neck tumors, are impressive, it has not been demonstrated unequivocally that radiation under hyperbaric conditions is superior to well fractionated, well conceived, conventional radiotherapy. Any resulting gain in survival from the addition of hyperbaric oxygen will be limited, especially with more advanced stages of disease. Well controlled studies, especially with earlier stage disease, are still necessary. It would be worthwhile to undertake such trials, especially with tumors of the head and neck constituting the most promising site of study, as others have noted, since even a 5% to 10% improvement in survival would mean many lives saved. Continued trials with hyperbaric oxygen, oxygen in other forms, neutrons and other particles, and radiation sensitizing drugs are all justified in an attempt to overcome the oxygen effect on human tumors.

show abstract

Radiotherapy of Advanced Carcinoma of the Oropharyngeal Region Under Hyperbaric Oxygenation

Cited by 34 publications

References 0 publications

Hyperbaric Oxygen Therapy and Quality of Life: A Systematic Review

Hyperbaric Oxygen Therapy and Quality of Life: A Systematic Review

Hyperbaric oxygenation for tumour sensitisation to radiotherapy

Hyperbaric oxygen in radiation therapy

Contact Info

Product

Resources

About